FDA Releases Draft Guidance on Assessing Cardiac Arrhythmias in New Drugs

Summary

The FDA has made available a draft guidance document outlining recommendations for assessing the potential of new non-antiarrhythmic drugs to cause cardiac arrhythmias, as part of the International Conference on Harmonisation's efforts to standardize pharmaceutical regulations.